The team’s research, detailed in the Journal of Clinical Investigation, builds on prior observations that TNBC tumors are heterogeneous, exhibiting different cellular compositions that include diverse populations of tumor and immune cells. Among these immune cells, neutrophils and macrophages stand out as critical players. Dr. Xiang Zhang, the study’s senior author at Baylor College of Medicine, emphasized that variability in this immune cell landscape dictates the specific resistance mechanism a tumor might develop. Epithelial-like TNBC tumors, which harbor both macrophages and neutrophils, principally utilize neutrophil-driven pathways to evade chemotherapy, whereas mesenchymal-like tumors, dominated by macrophages, exploit these cells’ unique functional shifts to survive treatment.

Utilizing a robust experimental framework that combined investigations of human patient tissue samples with sophisticated mouse models, the researchers were able to dissect these resistance pathways with high resolution. Their previous research highlighted neutrophils as key facilitators in epithelial-like TNBC resistance, but the current study delves into mesenchymal-like tumors to examine macrophages’ role. Strikingly, macrophages in these tumors are not mere bystanders; chemotherapy itself appears to reprogram these immune cells, converting them from tumor-fighting sentinels into agents that actively suppress the immune response and assist tumor survival.

Dr. Liqun Yu, a co-first author of the study, elaborated that reprogrammed macrophages engage in a paradoxical behavior: while they continue to engulf and clear cancer cells, they simultaneously produce immune-suppressive molecules such as C1q and resolvin. These compounds inhibit cytotoxic immune cell activity, thereby creating an immunosuppressive microenvironment favorable for tumor cells to persist despite chemotherapy. This dual functionality of macrophages introduces a complex layer of resistance, highlighting the intricate crosstalk between cancer cells and the immune system within the tumor microenvironment.

To counteract this macrophage-mediated resistance, the research team explored several therapeutic strategies aimed at either eliminating macrophages or blocking their recruitment into mesenchymal-like tumors. Remarkably, these interventions restored sensitivity to chemotherapy, indicating that disabling the immunosuppressive capabilities of macrophages could reinvigorate the body’s natural defense mechanisms against tumor cells. Additionally, antagonizing the molecules secreted by the reprogrammed macrophages further revived the immune system’s antitumor response, underscoring new potential drug targets for overcoming resistance.

The implications of these findings extend beyond understanding resistance mechanisms; they usher in a new paradigm for personalized TNBC treatment. By profiling a tumor’s immune cell composition prior to therapy—discerning whether it aligns more closely with epithelial-like or mesenchymal-like characteristics—clinicians could predict the specific pathways the tumor might exploit to resist chemotherapy. This proactive approach could enable tailored treatment regimens that preempt resistance, employing immune modulatory agents alongside standard chemotherapy to block the tumor’s escape routes.

Furthermore, the delineation of discrete, mutually exclusive resistance mechanisms challenges the traditional one-size-fits-all model prevalent in oncological therapy. As noted by Dr. Zhang, the study reinforces that TNBC is not a monolithic entity; its heterogeneity demands nuanced therapeutic interventions. Targeting neutrophil-driven pathways in epithelial-like tumors while simultaneously addressing macrophage-mediated resistance in mesenchymal-like tumors could offer a dual-pronged strategy that enhances treatment efficacy across the TNBC spectrum.

The investigative team credits their progress to the integration of patient-derived samples for clinical relevance and genetically engineered mouse models that offer mechanistic insights. This translational research framework bridges laboratory findings with potential clinical applications, accelerating the pathway to novel therapies. Co-author Bo Wei from the University of Texas MD Anderson Cancer Center also contributed pivotal expertise, underscoring the collaborative, multi-institutional effort necessary to tackle the complexity of TNBC.

The study was supported through various grants from leading institutions including the National Institutes of Health, the Department of Defense, the National Cancer Institute, and the Breast Cancer Research Foundation. Such financial backing reflects the critical importance of continuing to unravel the cellular and molecular underpinnings of cancer resistance, which remains a substantial barrier to curing aggressive cancers like TNBC.

In summary, this groundbreaking research reveals that therapeutic resistance in TNBC emerges from distinct myeloid immune circuits shaped by the tumor’s cellular composition. The interplay of neutrophils and macrophages in crafting resistance pathways underscores the adaptive capabilities of the tumor microenvironment under therapeutic pressure. Targeting these circuits offers a tantalizing prospect for developing more effective, personalized therapies—potentially transforming the prognosis for patients afflicted by one of the most refractory breast cancer subtypes.

Subject of Research: Human tissue samples
Article Title: Inflammation- and resolution-programmed myeloid circuits govern therapeutic resistance in epithelial and mesenchymal triple-negative breast cancer
News Publication Date: 17-Feb-2026
Web References:

• Journal of Clinical Investigation
• Previous related study
  References: DOI 10.1172/JCI198815
  Keywords: Triple-negative breast cancer, TNBC, therapy resistance, macrophages, neutrophils, immunosuppression, tumor microenvironment, personalized medicine, chemotherapy resistance, immune modulation

Central to these metabolic shifts is the enhanced uptake and de novo synthesis of fatty acids, which not only fulfill the bioenergetic demands of rapidly proliferating cancer cells but also supply essential components for membrane biogenesis and signaling cascades. Enzymes such as fatty acid synthase (FASN) and transport proteins including CD36 and fatty acid-binding protein 4 (FABP4) are markedly upregulated in breast tumor cells. This overexpression drives lipid accumulation, facilitating membrane remodeling that supports cellular motility and invasiveness—a hallmark of metastatic competence.

Cholesterol metabolism also emerges as a vital axis in breast cancer pathobiology. Elevated cholesterol biosynthesis alongside increased levels of 27-hydroxycholesterol (27HC), a bioactive cholesterol metabolite, has been implicated in accelerating tumor progression. 27HC functions dually as an agonist for estrogen receptors and modulator of immune cell behavior within the tumor microenvironment. Proteins integral to cholesterol homeostasis, including SREBP2, NSDHL, and STARD4, are often dysregulated, reinforcing malignant phenotypes and enabling immune evasion by remodeling immune checkpoints and inflammatory responses.

The sphingolipid metabolic network reveals an intriguing paradox in breast cancer biology. Ceramide accumulation is recognized for its tumor-suppressive capacity, promoting apoptosis and enhancing sensitivity to chemotherapeutic agents. Conversely, glycosylated sphingolipid derivatives such as Globo-H ceramide and GD2 are associated with tumorigenesis, angiogenesis, and the maintenance of cancer stem-like cells. This dichotomy underscores the complexity of lipid-mediated signaling pathways and their divergent roles in cancer cell fate determination.

A particularly nefarious consequence of lipid metabolic reprogramming lies in its facilitation of epithelial-to-mesenchymal transition (EMT). EMT endows cancer cells with increased migratory capabilities and resistance to apoptosis, an effect mediated by molecular regulators such as the fatty acid elongase ELOVL2, sphingomyelin synthase 2 (SGMS2), and chemokine CXCL8. These factors orchestrate intricate signaling networks involving TGF-β, PI3K/AKT, and sterol regulatory element-binding proteins (SREBPs), effectively rewiring gene expression programs to favor a mesenchymal, invasive phenotype.

Moreover, the tumor immune microenvironment (TIME) is not a passive bystander but dynamically adapts to lipid-driven signals. Immunosuppressive M2 macrophages and cancer-associated fibroblasts (CAFs) reprogram their lipid metabolism, reshaping cytokine profiles and extracellular matrix components to support tumor progression. Simultaneously, cytotoxic CD8+ T cells experience lipid-mediated functional impairment, weakening anti-tumor immunity and contributing to immune evasion mechanisms.

Resistance to conventional breast cancer therapies—including chemotherapy, endocrine treatments, HER2-targeted agents, and immune checkpoint blockade—is deeply intertwined with lipid metabolic rewiring. Tumor cells amplify expression of lipid transporters like CD36, lipid synthesis enzymes such as FASN, and mitochondrial fatty acid oxidation components including CPT1, thereby circumventing apoptotic triggers and diminishing intracellular drug accumulation. G protein-coupled receptor 120 (GPR120) further mediates pro-survival lipid signaling contributing to the maintenance of cancer stemness and therapy resistance.

Beyond intrinsic cancer cell alterations, cross-talk between lipid metabolism and oncogenic signaling pathways reveals additional complexity. Activation of SREBP1/2 transcription factors regulates genes involved in lipid biosynthesis and uptake, coalescing with pathways modulated by TGF-β and PI3K/AKT to promote malignant behaviors. Downregulation of enzymes like ELOVL2 disrupts lipid homeostasis, potentiating EMT and metastatic dissemination, highlighting the interplay between metabolic enzymes and cellular phenotypic plasticity.

The role of cholesterol metabolites extends past tumor intrinsic functions, as 27HC modulates local immunosuppression by influencing tumor-infiltrating lymphocytes and facilitating escape from immune surveillance. This duality creates therapeutic challenges, particularly in hormone receptor-positive breast cancers where estrogen signaling intersects with lipid metabolic pathways, necessitating refined strategies to target this metabolic-immune axis.

Emerging therapeutic interventions aimed at targeting lipid metabolism show potential in overcoming drug resistance. Pharmacological inhibitors of FASN, blockers of CD36-mediated fatty acid uptake, and modulators of sphingolipid pathways are under investigation for their capacity to sensitize tumors to existing treatments. Combinatorial approaches targeting lipid metabolism alongside conventional or immune-based therapies may enable more durable responses.

Encapsulating these insights, lipid metabolic reprogramming represents a fundamental axis driving breast cancer progression, metastatic competence, immune evasion, and therapeutic resistance. Deciphering the molecular underpinnings of this metabolic landscape opens promising avenues for novel biomarker identification and the development of metabolism-targeted therapies that could revolutionize breast cancer management.

As research delves deeper into the metabolic vulnerabilities of breast cancer, especially aggressive subtypes like TNBC, the integration of lipidomics with genomic and proteomic data stands to refine precision oncology approaches. Such multidisciplinary efforts are essential to translating mechanistic discoveries into clinical gains, ultimately improving patient survival and quality of life.

Subject of Research: Lipid metabolism in breast cancer progression and therapy resistance, focusing on metabolic reprogramming mechanisms in triple-negative breast cancer.

Article Title: Lipid metabolism involved in progression and drug resistance of breast cancer.

Web References: http://dx.doi.org/10.1016/j.gendis.2024.101376

References: Wenxiang Fu, Aijun Sun, Huijuan Dai, Lipid metabolism involved in progression and drug resistance of breast cancer, Genes & Diseases, Volume 12, Issue 4, 2025, 101376

Image Credits: Genes & Diseases

Keywords: Breast cancer, lipid metabolism, fatty acids, cholesterol, sphingolipids, epithelial-mesenchymal transition, drug resistance, tumor microenvironment, triple-negative breast cancer, FASN, CD36, 27-hydroxycholesterol

In examining mouse models, researchers have identified that the survival of TNBC cells following therapy is intricately linked to the accumulation of lipid droplets enriched with Omega-6 fatty acids. This lipid saturation not only affects the tumor cells but also alters nearby immune cells, particularly neutrophils. These alterations are strikingly significant, as neutrophils, typically tasked with mounting an anti-tumor response, are reprogrammed under these circumstances to facilitate tumor promotion. The study underscores a shift in the interaction dynamics between cancer cells and immune cells that is critical to understanding how tumors can evade treatment.

The findings reveal that tumor cells actively engage in a process where they transfer lipid droplets to the surrounding neutrophils. This transfer is not merely a passive occurrence but a strategic manipulation. By transferring these lipid-rich droplets, the tumor influences the function of neutrophils, effectively reprogramming them from defenders of the immune system to allies of tumor growth. This novel understanding of lipid metabolism presents a paradigm shift in our comprehension of the tumor microenvironment and its role in influencing systemic therapy outcomes.

The principal authors of this study, Dr. Liqun Yu and Dr. Xiang H.-F. Zhang, emphasize the broader implications of their findings. Dr. Zhang notes that while previous research has predominantly focused on fatty acid metabolism as a source of energy for cellular processes, their study introduces the perspective that fatty acids also serve as precursors to immunosuppressive signals utilized by cancer cells. This dual role of fatty acids complicates the landscape of cancer therapy and suggests that manipulating lipid metabolism could offer therapeutic reevaluation.

In practical terms, the researchers highlighted that therapeutic resistance characteristic of TNBC could potentially be reversed by disrupting the formation of lipid droplets in tumor cells. Utilizing pharmacological agents or dietary modifications to inhibit Omega-6 fatty acid intake represents a promising frontline in combating resistance. By adopting a diet low in Omega-6 fatty acids, patients may not only experience resensitization of tumors to existing chemotherapy and immunotherapy regimens but could also mitigate the overall immunosuppressive environment established by the tumor.

The study’s implications extend to dietary recommendations for TNBC patients, aligning with general nutritional advice to lower the intake of red meat, fats, and sodium. However, it specifically brings to light the necessity of focusing on Omega-6 fatty acids, which have been linked to inflammatory pathways and metabolic dysregulation within the tumor microenvironment. This approach might empower patients seeking practical strategies to complement their treatment regimens with dietary choices.

While the study presents compelling preliminary data, further research is essential to evaluate the efficacy of these dietary interventions in clinical settings. The exploration of therapeutic options that specifically block fatty acid accumulation is another exciting avenue that the researchers are pursuing, with the objective of dismantling the immunosuppressive signals that facilitate tumor survival and growth.

These findings are an essential scholarly contribution, supported by robust funding from entities including the U.S. Department of Defense, the National Cancer Institute, and various foundations dedicated to breast cancer research. The study’s depth and breadth highlight the urgent need for comprehensive cancer research that not only probes the biological mechanisms but also considers the translational implications of these discoveries for clinical practice.

The study has garnered attention not only for its scientific rigor but also for the potential it holds in affecting patient outcomes. By translating laboratory findings into actionable insights, researchers hope to bridge the gap between experimental science and real-world clinical applications, ultimately improving the prognosis for patients with TNBC, a subtype that remains challenging due to its aggressive nature and limited treatment options.

In summary, Baylor College of Medicine’s study marks a significant advancement in unraveling the complex interplay between lipid accumulation and immune evasion in triple-negative breast cancer. As researchers continue to delve into the relationship between diet, metabolism, and cancer biology, we can anticipate a new frontier in cancer treatment that prioritizes innovative strategies alongside traditional approaches. This work exemplifies the dedication of scientists to not only understand cancer at a biological level but also to make tangible differences in the lives of those affected by this insidious disease.

Subject of Research: Mechanisms of therapy resistance in triple-negative breast cancer due to lipid accumulation and immune suppression.
Article Title: Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer.
News Publication Date: March 28, 2025
Web References: Immunity Journal
References: To be determined upon publication.
Image Credits: To be determined upon publication.
Keywords: Triple-negative breast cancer, lipid accumulation, immune suppression, chemotherapy resistance, immunotherapy, Omega-6 fatty acids, tumor microenvironment.